4/15
08:11 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at HC Wainwright from $49.00 to $53.00. They now have a "buy" rating on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at HC Wainwright from $49.00 to $53.00. They now have a "buy" rating on the stock.
4/11
04:01 pm
bbio
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
4/7
07:20 am
bbio
AIG Technology Strategy Company Profile 2025 - Digital Transformation Strategies and Innovation Programs [Yahoo! Finance]
Low
Report
AIG Technology Strategy Company Profile 2025 - Digital Transformation Strategies and Innovation Programs [Yahoo! Finance]
4/1
08:00 am
bbio
BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor, in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors
Medium
Report
BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor, in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors
3/31
10:00 am
bbio
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
Low
Report
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
3/31
09:04 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at Redburn Atlantic. They set a "buy" rating and a $50.00 price target on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at Redburn Atlantic. They set a "buy" rating and a $50.00 price target on the stock.
3/27
07:00 am
bbio
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (=90%), Approved in Japan to Treat ATTR-CM
Medium
Report
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (=90%), Approved in Japan to Treat ATTR-CM
3/24
09:15 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at JPMorgan Chase & Co. from $44.00 to $50.00. They now have an "overweight" rating on the stock.
Medium
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at JPMorgan Chase & Co. from $44.00 to $50.00. They now have an "overweight" rating on the stock.
3/24
07:36 am
bbio
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions [Yahoo! Finance]
Medium
Report
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions [Yahoo! Finance]
3/24
07:30 am
bbio
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions
Medium
Report
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions
3/21
04:00 pm
bbio
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
3/17
04:01 pm
bbio
BridgeBio Announces CFO Succession
Low
Report
BridgeBio Announces CFO Succession
2/26
12:17 pm
bbio
BridgeBio Pharma (BBIO): Among the Best Performing Mid Cap Stocks to Buy According to Analysts [Yahoo! Finance]
Neutral
Report
BridgeBio Pharma (BBIO): Among the Best Performing Mid Cap Stocks to Buy According to Analysts [Yahoo! Finance]
2/26
02:49 am
bbio
BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt
Low
Report
BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt
2/24
06:06 pm
bbio
BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt [Yahoo! Finance]
Low
Report
BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt [Yahoo! Finance]
2/24
04:09 pm
bbio
BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt
Low
Report
BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt
2/21
03:41 pm
bbio
BridgeBio's heart drug launch gets off to a fast start [Yahoo! Finance]
Low
Report
BridgeBio's heart drug launch gets off to a fast start [Yahoo! Finance]
2/21
01:15 pm
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at Citigroup Inc. from $45.00 to $49.00. They now have a "buy" rating on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at Citigroup Inc. from $45.00 to $49.00. They now have a "buy" rating on the stock.
2/21
12:41 pm
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $95.00 price target on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $95.00 price target on the stock.
2/21
11:10 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at Scotiabank from $49.00 to $52.00. They now have a "sector outperform" rating on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at Scotiabank from $49.00 to $52.00. They now have a "sector outperform" rating on the stock.
2/20
10:37 am
bbio
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update [Yahoo! Finance]
Low
Report
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update [Yahoo! Finance]
2/20
07:30 am
bbio
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update
Low
Report
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update
2/13
06:07 pm
bbio
BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025 [Yahoo! Finance]
High
Report
BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025 [Yahoo! Finance]
2/13
04:01 pm
bbio
BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025
High
Report
BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025
2/13
08:53 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $49.00 price target on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $49.00 price target on the stock.